JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed.

This article was originally published here.